Why Cellectis S.A.’s (CLLS) Stock Is Up 5.26%
As of Thursday, August 27, Cellectis S.A.’s CLLS share price has surged by 5.26%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Commentary & Analysis
Why Cellectis S.A.’s (CLLS) Stock Is Up 5.65%
As of Tuesday, August 25, Cellectis S.A.’s CLLS share price has surged by 5.65%, which has investors questioning if this is right time to sell.Michael Rose
Why Cellectis S.A.’s (CLLS) Stock Is Down 5.73%
As of Monday, August 24, Cellectis S.A.’s CLLS share price has dipped by 5.73%, which has investors questioning if this is right time to buy.Michael Rose
Why Cellectis S.A.’s (CLLS) Stock Is Down 8.65%
As of Friday, August 21, Cellectis S.A.’s CLLS share price has dipped by 8.65%, which has investors questioning if this is right time to buy.Michael Rose
Why Cellectis S.A.’s (CLLS) Stock Is Up 5.78%
As of Thursday, August 13, Cellectis S.A.’s CLLS share price has surged by 5.78%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CLLS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $256.9 | $298.4 | 29% |
|
| Shares Out (Mil) | 100.6 | 54.0 | 62% |
|
| Institutional Ownership | 87.9% | 93.1% | 56% |
|
| Float (Mil) | 46.8 | 41.4 | 45% |
|
| Beta | 2.75 | 0.94 | 97% |
|
| Avg Daily Volume (000s) | 18 | 504 | 20% |
|
| Price Change (52-week) |
27.1% | 62.0% | 68% |
|
| Growth | CLLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.0% | 14.0% | 41% |
|
| Net Income (5yr) | 3.6% | (10.0%) | 45% |
|
| EPS (5yr) | 18.8% | 16.0% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 19.1% | (15.6%) | 78% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.260) | ($0.818) | ($0.822) | |
| Month Ago EPS | na | ($0.867) | na | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | na | ($0.845) | na | |
| Year/Year Chg | 19.8% | 21.4% | 75.1% | |
| Financials | CLLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $64 | $37 | 22% |
|
| Net Income (TTM) (Mil) | ($65) | ($43) | 14% |
|
| EPS (TTM) | ($0.650) | ($1.400) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($32) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($24) | $2 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $72 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $116 | $186 | 22% |
|
| Valuation | CLLS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.11 | 2.89 | 82% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CLLS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.6% | 96% |
|
| Net Margin | (102.3%) | (75.3%) | 7% |
|
| ROA | (21.0%) | (47.6%) | 20% |
|
| ROE | (94.5%) | (55.0%) | 10% |
|
| Liabilities to Assets | 84.6% | 29.5% | 78% |
|
| F-Score | 3 | 3 | 18% |
|
Cellectis S.A. did not pass any screens on 8/26/2026.
